Disc Medicine, Inc. (NASDAQ:IRON) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Disc Medicine, Inc. (NASDAQ:IRONGet Free Report) have earned a consensus rating of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $62.57.

IRON has been the subject of several analyst reports. BMO Capital Markets restated an “outperform” rating and set a $70.00 price target (up previously from $50.00) on shares of Disc Medicine in a report on Monday, June 17th. Morgan Stanley reduced their price objective on shares of Disc Medicine from $75.00 to $40.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 2nd. Raymond James raised their price objective on shares of Disc Medicine from $40.00 to $43.00 and gave the stock an “outperform” rating in a research report on Friday, May 10th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of Disc Medicine in a research report on Friday, June 14th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $85.00 price objective on shares of Disc Medicine in a research report on Tuesday, May 28th.

Read Our Latest Stock Analysis on Disc Medicine

Insider Activity at Disc Medicine

In related news, Director William Richard White sold 2,560 shares of Disc Medicine stock in a transaction on Thursday, April 11th. The shares were sold at an average price of $31.80, for a total value of $81,408.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.24% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Disc Medicine

Several large investors have recently bought and sold shares of the stock. California State Teachers Retirement System lifted its stake in Disc Medicine by 37.2% during the 1st quarter. California State Teachers Retirement System now owns 11,800 shares of the company’s stock valued at $735,000 after acquiring an additional 3,200 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Disc Medicine by 17.7% during the 1st quarter. Janus Henderson Group PLC now owns 521,773 shares of the company’s stock valued at $32,465,000 after acquiring an additional 78,595 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Disc Medicine by 59.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 944,213 shares of the company’s stock valued at $58,788,000 after acquiring an additional 353,382 shares in the last quarter. Vanguard Group Inc. lifted its stake in Disc Medicine by 2.4% during the 1st quarter. Vanguard Group Inc. now owns 782,751 shares of the company’s stock valued at $48,734,000 after acquiring an additional 18,207 shares in the last quarter. Finally, Lord Abbett & CO. LLC bought a new position in Disc Medicine during the 1st quarter valued at $7,429,000. 83.70% of the stock is currently owned by institutional investors.

Disc Medicine Stock Performance

Disc Medicine stock opened at $44.98 on Tuesday. Disc Medicine has a 52-week low of $25.60 and a 52-week high of $77.60. The firm has a 50 day moving average price of $33.90 and a two-hundred day moving average price of $50.60. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of -13.31 and a beta of 0.51.

Disc Medicine (NASDAQ:IRONGet Free Report) last released its quarterly earnings results on Thursday, May 9th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.09). As a group, equities research analysts predict that Disc Medicine will post -4.56 EPS for the current fiscal year.

Disc Medicine Company Profile

(Get Free Report

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

Further Reading

Analyst Recommendations for Disc Medicine (NASDAQ:IRON)

Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.